This undated photo issued by the University of Oxford shows of vial of coronavirus vaccine developed by AstraZeneca and Oxford University, in Oxford, England. (University of Oxford/John Cairns via AP)

This undated photo issued by the University of Oxford shows of vial of coronavirus vaccine developed by AstraZeneca and Oxford University, in Oxford, England. (University of Oxford/John Cairns via AP)

Canada can make vaccines, just not the ones leading the COVID-19 race

Canada has spent more than $1 billion to pre-order seven different developing COVID-19 vaccines

The head of a Canadian biotech industry association says Canada can and does make vaccines — just not the ones expected first to help stop the COVID-19 pandemic.

Prime Minister Justin Trudeau created a firestorm Tuesday when he said Canadians will have to wait a bit to get vaccinated for COVID-19 because the first doses off the production lines will be used in the countries where they are made.

So while vaccinations might start next month in the United States, the United Kingdom and Germany, it will be January at the earliest before any doses are injected in this country.

Canada, said Trudeau, “no longer has any domestic production capacity for vaccines” and it makes sense that the countries that do will prioritize their own citizens.

Andrew Casey, the CEO of BioteCanada, told The Canadian Press Wednesday that Canada does produce vaccines but the technology for the leading COVID-19 vaccine candidates is so new, the manufacturing capacity is being built alongside the vaccines themselves.

“This is the first time the technology has actually been applied,” he said. “So you have to then build the facility to manufacture at scale, which is a challenge.”

While pharmaceutical company Sanofi has a vaccine plant in Toronto and GlaxoSmithKline has one in Quebec, both make protein-based vaccines, such as the more familiar ones Canadians get every year for the flu.

Canada has spent more than $1 billion to pre-order seven different developing COVID-19 vaccines, and only one being developed jointly by Sanofi and GlaxoSmithKline uses the protein technology.

The first two vaccines expected on the market, from Pfizer and Moderna, each use genetic material known as messenger ribonucleic acid or mRNA. A third with promising trial results, from AstraZeneca, uses a modified common-cold virus that normally infects chimpanzees. Each type trains the human body to develop antibodies to SARS-CoV-2, the virus that causes COVID-19.

Casey said a protein-vaccine maker can’t just start making the bioengineered vaccines.

“One is like making wine, one’s like making Coke,” he said. “Yes, they both grow in bottles. Yes, you can drink both out of a glass. But the manufacturing processes used for the two is so completely different. You can’t just say well, we’ll shut down the protein one, and we’ll switch over to the mRNA.”

READ MORE: Canada’s inability to manufacture vaccines in-house will delay distribution: Trudeau

Conservative health critic Michelle Rempel Garner demanded in question period Wednesday that the government explain whether Canada had even tried to convince the companies to make their products here.

Trudeau didn’t answer, but if those negotiations happened, they have not been successful.

Pfizer is expanding production facilities in Kalamazoo, Mich. and Puurs, Belgium to produce most of its vaccine. The company has said it is open to others manufacturing it, but that the technology is difficult to transfer.

Moderna has a 10-year exclusive agreement with Swiss-based Lonza Group AC to make its vaccine, mainly in facilities in New Hampshire and Switzerland. Lonza chairman Albert Baehny said earlier this month the new technology meant Lonza had to remake its production lines “from scratch.”

AstraZeneca, which has promised three billion doses of its vaccine, has signed contract deals with at least two dozen manufacturers around the world to produce its vaccine but not in Canada.

A spokesman for Innovation Minister Navdeep Bains said the biomanufacturing sector has been declining in Canada since the mid-1980s.

“When this pandemic began Canada had no flexible, large-scale, bio-manufacturing capacity suitable for a COVID-19 vaccine,” said John Power.

He said Canada has been working with experts to address the issue and has made investments, including $140 million in a new National Research Council plant in Montreal.

The NRC said Wednesday the Biologics Manufacturing Centre will be finished next July. It doesn’t have an agreement yet to produce a specific vaccine, but is being built so it can produce several biologic vaccines, including of the type being made by AstraZeneca. It will not be able to make mRNA vaccines like those from Moderna or Pfizer.

It is supposed to be able to produce two million doses a month before the end of 2021.

A spokeswoman for GlaxoSmithKline told The Canadian Press the company’s Ste-Foy, Que., plant will be part of production of the GSK vaccine eventually but timelines and specifics aren’t yet available.

A Canadian-made vaccine from Quebec-based Medicago is also expected to be in production in Canada next year.

Medicago CEO Bruce Clark said the company has been able to adapt a vaccine for influenza to target COVID-19 instead, noting such an adaptation is one of the advantages of biologic vaccines. But Clark said one of the disadvantages is that it’s harder to transfer the technology of biologics to be made in other places.

Medicago has facilities in Quebec and North Carolina and is building a new one in Quebec. The existing ones can make about 50 million doses by the end of next year, while the new plant will be able to do as many as a billion annually.

The company has been talking to the federal government for years to get funding for a “full-scale manufacturing facility,” he said.

“We were not successful,” said Clark. “It’s really only been in the context of the pandemic that we’ve seen funds be freed up to commit to capacity in Canada.”

Last month Ottawa agreed to provide $173 million to Medicago for research on its vaccine and construction of an expanded facility. Clark said the 2023 completion date for the new plant could be bumped up with more money.

None of the vaccines in question have finished clinical trials and all must also be approved by Health Canada before they can be used here.

Mia Rabson, The Canadian Press


Like us on Facebook and follow us on Twitter.

Want to support local journalism during the pandemic? Make a donation here.

Coronavirusvaccines

Just Posted

Jean-Pierre Antonio
Article chronicling haiku in Japanese internment camp near Hope wins award

Tashme Haiku Club’s work was preserved and recently translated, authors write

(Adam Louis/Observer)
PHOTOS: Students leap into action in track events at Kent Elementary

At Kent Elementary, when the sun’s outside, the fun’s outside. The intermediate… Continue reading

Kindergarten kids from Evans elementary school in Chilliwack painted rocks with orange hearts and delivered them to Sto:lo Elders Lodge recently after learning about residential schools. (Laura Bridge photo)
Kindergarten class paints rocks with orange hearts in Chilliwack for local elders

‘Compassion and empathy’ being shown by kids learning about residential schools

Chilliwack potter Cathy Terepocki (left) and Indigenous enhancement teachers Val Tosoff (striped top) and Christine Seymour (fuchsia coat), along with students at Vedder middle school, look at some of the 500-plus pinch pots on Thursday, June 10 made by the kids to honour the 215 children found at Kamloops Indian Residential School. (Jenna Hauck/ Chilliwack Progress)
Chilliwack students make hundreds of tiny clay pots in honour of 215 Indigenous children

‘I think the healing process has begun,’ says teacher about Vedder middle school project

Image by Free-Photos from Pixabay
Webinar looks at sexual abuse prevention among adolescents

Vancouver/Fraser Valley CoSA hosts free online session on June 15

At an outdoor drive-in convocation ceremony, Mount Royal University bestows an honorary Doctor of Laws on Blackfoot Elder and residential school survivor Clarence Wolfleg in Calgary on Tuesday, June 8, 2021. THE CANADIAN PRESS/Jeff McIntosh
‘You didn’t get the best of me’: Residential school survivor gets honorary doctorate

Clarence Wolfleg receives honorary doctorate from Mount Royal University, the highest honour the school gives out

The Great Ogopogo Bathtub Race has been held in Summerland as a fundraising event. Do you know which Canadian city introduced this sport? (Black Press file photo)
QUIZ: A summer’s day at the water

How much do you know about boats, lakes and water?

Two-year-old Ivy McLeod laughs while playing with Lucky the puppy outside their Chilliwack home on Thursday, June 10, 2021. (Jenna Hauck/ Chilliwack Progress)
VIDEO: B.C. family finds ‘perfect’ puppy with limb difference for 2-year-old Ivy

Ivy has special bond with Lucky the puppy who was also born with limb difference

A million-dollar ticket was sold to an individual in Vernon from the Lotto Max draw Friday, June 11, 2021. (Photo courtesy of BCLC)
Lottery ticket worth $1 million sold in Vernon

One lucky individual holds one of 20 tickets worth $1 million from Friday’s Lotto Max draw

Join Black Press Media and Do Some Good
Join Black Press Media and Do Some Good

Pay it Forward program supports local businesses in their community giving

Cannabis bought in British Columbia (Ashley Wadhwani/Black Press Media)
Is it time to start thinking about greener ways to package cannabis?

Packaging suppliers are still figuring eco-friendly and affordable packaging options that fit the mandates of Cannabis Regulations

“65 years, I’ve carried the stories in my mind and live it every day,” says Jack Kruger. (Athena Bonneau)
‘Maybe this time they will listen’: Survivor shares stories from B.C. residential school

Jack Kruger, living in Syilx territory, wasn’t surprised by news of 215 children’s remains found on the grounds of the former Kamloops Indian Residential School

A logging truck carries its load down the Elaho Valley near in Squamish, B.C. in this file photo. THE CANADIAN PRESS/Chuck Stoody
Squamish Nation calls for old-growth logging moratorium in its territory

The nation says 44% of old-growth forests in its 6,900-square kilometre territory are protected while the rest remain at risk

Most Read